➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Harvard Business School
Colorcon
McKinsey
Merck

Last Updated: June 15, 2021

DrugPatentWatch Database Preview

SYNAGIS Drug Profile


Email this page to a colleague

« Back to Dashboard

Recent Clinical Trials for SYNAGIS

Identify potential brand extensions & biosimilar entrants

SponsorPhase
IQVIA Services Japan K.K.Phase 2
AbbViePhase 3
The University of Texas Health Science Center, HoustonN/A

See all SYNAGIS clinical trials

Recent Litigation for SYNAGIS

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Reckitt Benckiser Pharmaceuticals Inc. v. Watson Laboratories Inc.2013-10-08

See all SYNAGIS litigation

PTAB Litigation
PetitionerDate
2017-12-20

See all SYNAGIS litigation

Pharmacology for SYNAGIS
Ingredient-typeAntibodies, Monoclonal
Mechanism of ActionFusion Protein Inhibitors

Patent Text Search: US Patents for SYNAGIS

These patents were identified by searching patent claims

Supplementary Protection Certificates for SYNAGIS

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
CR 2016 00031 Denmark   Get Started Free PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; NAT. REG. NO/DATE: EU/1/98/067/003-004 20140326; FIRST REG. NO/DATE: EU EU/1/98/067 20140326
132016000025345 Italy   Get Started Free PRODUCT NAME: TRASTUZUMAB PER USO SOTTOCUTANEO(HERCEPTIN); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/00/145/002, 20130828
122015000061 Germany   Get Started Free PRODUCT NAME: TRASTUZUMAB UND RECOMBINANTE HUMANE HYALURONIDASE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
300822 Netherlands   Get Started Free PRODUCT NAME: RITUXIMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/98/067/003 - UITVOERINGSBESLUIT C(2014)2048 20140326
122016000049 Germany   Get Started Free PRODUCT NAME: RITUXIMAB UND REKOMBINANTE HUMANE HYALURONIDASE; NAT. REGISTRATION NO/DATE: EU/1/98/067/003 20140321; FIRST REGISTRATION: EU EU/1/98/067/003 20140621
PA2016022 Lithuania   Get Started Free PRODUCT NAME: RITUKSIMABAS; REGISTRATION NO/DATE: EU/1/98/067/001-002 20140321
CA 2016 00031 Denmark   Get Started Free PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: EU/1/98/067 20140326
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Colorcon
Express Scripts
McKesson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.